» Articles » PMID: 29959198

Detection of Splicing Abnormalities and Genotype-Phenotype Correlation in X-linked Alport Syndrome

Abstract

Background: X-linked Alport syndrome (XLAS) is a progressive hereditary nephropathy caused by mutations in the gene. Genotype-phenotype correlation in male XLAS is relatively well established; relative to truncating mutations, nontruncating mutations exhibit milder phenotypes. However, transcript comparison between XLAS cases with splicing abnormalities that result in a premature stop codon and those with nontruncating splicing abnormalities has not been reported, mainly because transcript analysis is not routinely conducted in patients with XLAS.

Methods: We examined transcript expression for all patients with suspected splicing abnormalities who were treated at one hospital between January of 2006 and July of 2017. Additionally, we recruited 46 males from 29 families with splicing abnormalities to examine genotype-phenotype correlation in patients with truncating (=21, from 14 families) and nontruncating (=25, from 15 families) mutations at the transcript level.

Results: We detected 41 XLAS families with abnormal splicing patterns and described novel XLAS atypical splicing patterns (=14) other than exon skipping caused by point mutations in the splice consensus sequence. The median age for developing ESRD was 20 years (95% confidence interval, 14 to 23 years) among patients with truncating mutations and 29 years (95% confidence interval, 25 to 40 years) among patients with nontruncating mutations (=0.001).

Conclusions: We report unpredictable atypical splicing in the gene in male patients with XLAS and reveal that renal prognosis differs significantly for patients with truncating versus nontruncating splicing abnormalities. Our results suggest that splicing modulation should be explored as a therapy for XLAS with truncating mutations.

Citing Articles

Intronic Variants at Third to Fifth Nucleotides Cause Alport Syndrome.

Kitakado H, Horinouchi T, Aoyama S, Kimura Y, Inoki Y, Tanaka Y Kidney Int Rep. 2025; 10(2):516-521.

PMID: 39990911 PMC: 11843108. DOI: 10.1016/j.ekir.2024.11.016.


Trichostatin A suppresses hearing loss by reducing oxidative stress and inflammation in an Alport syndrome model.

Nam Y, Gi E, Ko Y, Lee S, Cho H PLoS One. 2025; 20(2):e0316033.

PMID: 39908276 PMC: 11798502. DOI: 10.1371/journal.pone.0316033.


Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome.

Inoki Y, Horinouchi T, Yamamura T, Ishimori S, Ichikawa Y, Tanaka Y Kidney360. 2024; 5(10):1510-1517.

PMID: 39137047 PMC: 11556934. DOI: 10.34067/KID.0000000000000547.


Aberrant Splicing of Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series.

Li Y, Yan X, Luo Z, Fu X, Li Z, Xu Q Int J Nephrol Renovasc Dis. 2024; 17:167-174.

PMID: 38855711 PMC: 11162193. DOI: 10.2147/IJNRD.S459363.


Explaining Alport syndrome-lessons from the adult nephrology clinic.

Mabillard H, Ryan R, Tzoumas N, Gear S, Sayer J J Rare Dis (Berlin). 2024; 3(1):14.

PMID: 38745975 PMC: 11088994. DOI: 10.1007/s44162-024-00036-z.


References
1.
Knox K, Bajorska A, Feng C, Tang W, Wu P, Tu X . Survival analysis for observational and clustered data: an application for assessing individual and environmental risk factors for suicide. Shanghai Arch Psychiatry. 2014; 25(3):183-94. PMC: 4054555. DOI: 10.3969/j.issn.1002-0829.2013.03.10. View

2.
Nakanishi K, Nozu K, Hiramoto R, Minamikawa S, Yamamura T, Fujimura J . A comparison of splicing assays to detect an intronic variant of the OCRL gene in Lowe syndrome. Eur J Med Genet. 2017; 60(12):631-634. DOI: 10.1016/j.ejmg.2017.08.001. View

3.
MARTIN P, Tryggvason K . Two novel alternatively spliced 9-bp exons in the COL4A5 gene. Pediatr Nephrol. 2001; 16(1):41-4. DOI: 10.1007/s004670000462. View

4.
Yamamura T, Nozu K, Fu X, Nozu Y, Ye M, Shono A . Natural History and Genotype-Phenotype Correlation in Female X-Linked Alport Syndrome. Kidney Int Rep. 2017; 2(5):850-855. PMC: 5733817. DOI: 10.1016/j.ekir.2017.04.011. View

5.
Monaco A, Bertelson C, Moser H, Kunkel L . An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988; 2(1):90-5. DOI: 10.1016/0888-7543(88)90113-9. View